283 related articles for article (PubMed ID: 29425146)
1. Nanoparticle-Based Strategies to Treat Neuro-Inflammation.
Poupot R; Bergozza D; Fruchon S
Materials (Basel); 2018 Feb; 11(2):. PubMed ID: 29425146
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
3. Potential toxicity of engineered nanoparticles in mammalian germ cells and developing embryos: treatment strategies and anticipated applications of nanoparticles in gene delivery.
Das J; Choi YJ; Song H; Kim JH
Hum Reprod Update; 2016 Sep; 22(5):588-619. PubMed ID: 27385359
[TBL] [Abstract][Full Text] [Related]
4. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
Zhao X; Ye Y; Ge S; Sun P; Yu P
Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
[TBL] [Abstract][Full Text] [Related]
5. Risks from accidental exposures to engineered nanoparticles and neurological health effects: a critical review.
Simkó M; Mattsson MO
Part Fibre Toxicol; 2010 Dec; 7():42. PubMed ID: 21176150
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
[TBL] [Abstract][Full Text] [Related]
7. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier.
Tan Q; Zhao S; Xu T; Wang Q; Lan M; Yan L; Chen X
J Mater Chem B; 2022 Nov; 10(45):9314-9333. PubMed ID: 36349976
[TBL] [Abstract][Full Text] [Related]
8. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review.
Lossinsky AS; Shivers RR
Histol Histopathol; 2004 Apr; 19(2):535-64. PubMed ID: 15024715
[TBL] [Abstract][Full Text] [Related]
9. Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.
Alajangi HK; Kaur M; Sharma A; Rana S; Thakur S; Chatterjee M; Singla N; Jaiswal PK; Singh G; Barnwal RP
Mol Brain; 2022 Jun; 15(1):49. PubMed ID: 35650613
[TBL] [Abstract][Full Text] [Related]
10. Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.
Shahjin F; Chand S; Yelamanchili SV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):443-458. PubMed ID: 31485884
[TBL] [Abstract][Full Text] [Related]
11. Paracrine signalling of inflammatory cytokines from an in vitro blood brain barrier model upon exposure to polymeric nanoparticles.
Raghnaill MN; Bramini M; Ye D; Couraud PO; Romero IA; Weksler B; Åberg C; Salvati A; Lynch I; Dawson KA
Analyst; 2014 Mar; 139(5):923-30. PubMed ID: 24195103
[TBL] [Abstract][Full Text] [Related]
12. Recent advances and challenges on applications of nanotechnology in food packaging. A literature review.
Enescu D; Cerqueira MA; Fucinos P; Pastrana LM
Food Chem Toxicol; 2019 Dec; 134():110814. PubMed ID: 31520669
[TBL] [Abstract][Full Text] [Related]
13. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS.
Silva GA
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S4. PubMed ID: 19091001
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.
Soni S; Ruhela RK; Medhi B
Adv Pharm Bull; 2016 Sep; 6(3):319-335. PubMed ID: 27766216
[No Abstract] [Full Text] [Related]
16. Nanobiotechnology-based drug delivery in brain targeting.
Dinda SC; Pattnaik G
Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
[TBL] [Abstract][Full Text] [Related]
17. Nanobiotechnology-based strategies for crossing the blood-brain barrier.
Jain KK
Nanomedicine (Lond); 2012 Aug; 7(8):1225-33. PubMed ID: 22931448
[TBL] [Abstract][Full Text] [Related]
18. Review and Prospects on the Ecotoxicity of Mixtures of Nanoparticles and Hybrid Nanomaterials.
Zhang F; Wang Z; Peijnenburg WJGM; Vijver MG
Environ Sci Technol; 2022 Nov; 56(22):15238-15250. PubMed ID: 36196869
[TBL] [Abstract][Full Text] [Related]
19. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
20. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
